Whereas, the integrated angiogenesis activity has been found to be correlated with PRAD progression, thus the identified 19 ARGs instead of one single ARG could become the molecularly therapeutic targets for PRAD. This evidence concerns the gene SERPINA2 and prostate adenocarcinoma.